Salarius Pharmaceuticals Inc (SLRX) - Total Assets
Based on the latest financial reports, Salarius Pharmaceuticals Inc (SLRX) holds total assets worth $6.10 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SLRX debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Salarius Pharmaceuticals Inc - Total Assets Trend (2014–2024)
This chart illustrates how Salarius Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See SLRX net asset value for net asset value and shareholders' equity analysis.
Salarius Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Salarius Pharmaceuticals Inc's total assets of $6.10 Million consist of 98.8% current assets and 1.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Salarius Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SLRX market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Salarius Pharmaceuticals Inc's current assets represent 98.8% of total assets in 2024, an increase from 96.1% in 2014.
- Cash Position: Cash and equivalents constituted 80.5% of total assets in 2024, down from 95.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Salarius Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Salarius Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Salarius Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.49 | 4.09 | 5.70 |
| Quick Ratio | 5.49 | 4.09 | 5.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.96 Million | $2.89 Million | $13.02 Million |
Salarius Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Salarius Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.13 |
| Latest Market Cap to Assets Ratio | 1.59 |
| Asset Growth Rate (YoY) | -54.1% |
| Total Assets | $3.02 Million |
| Market Capitalization | $4.81 Million USD |
Valuation Analysis
Above Book Valuation: The market values Salarius Pharmaceuticals Inc's assets above their book value (1.59x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Salarius Pharmaceuticals Inc's assets decreased by 54.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Salarius Pharmaceuticals Inc (2014–2024)
The table below shows the annual total assets of Salarius Pharmaceuticals Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.02 Million | -54.10% |
| 2023-12-31 | $6.59 Million | -55.04% |
| 2022-12-31 | $14.65 Million | -64.12% |
| 2021-12-31 | $40.83 Million | +63.78% |
| 2020-12-31 | $24.93 Million | +79.44% |
| 2019-12-31 | $13.89 Million | +33.73% |
| 2018-12-31 | $10.39 Million | -70.31% |
| 2017-12-31 | $34.99 Million | -44.64% |
| 2016-12-31 | $63.21 Million | -33.51% |
| 2015-12-31 | $95.07 Million | +166.96% |
| 2014-12-31 | $35.61 Million | -- |
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufac… Read more